TrovaGene (TROV) Upgraded to “Hold” by Zacks Investment Research
TrovaGene (NASDAQ:TROV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Saturday.
According to Zacks, “Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics’ patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. “
TROV has been the topic of a number of other reports. Maxim Group upgraded shares of TrovaGene from a “hold” rating to a “buy” rating in a research report on Friday, June 15th. ValuEngine upgraded shares of TrovaGene from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Finally, HC Wainwright set a $7.00 price target on shares of TrovaGene and gave the company a “buy” rating in a research report on Monday, June 4th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $19.17.
In other news, Director Rodney S. Markin purchased 41,200 shares of the business’s stock in a transaction that occurred on Wednesday, June 20th. The shares were acquired at an average cost of $0.85 per share, for a total transaction of $35,020.00. Following the transaction, the director now directly owns 63,810 shares of the company’s stock, valued at approximately $54,238.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.30% of the company’s stock.
A hedge fund recently raised its stake in TrovaGene stock. Renaissance Technologies LLC lifted its position in TrovaGene Inc (NASDAQ:TROV) by 58.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 203,802 shares of the medical research company’s stock after acquiring an additional 75,131 shares during the period. Renaissance Technologies LLC owned approximately 1.15% of TrovaGene worth $157,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 48.63% of the company’s stock.
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.
Featured Story: Earnings Per Share
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.